BofA lowered the firm’s price target on MeiraGTx (MGTX) to $18 from $19 and keeps a Buy rating on the shares. The deal with Janssen (JNJ) removes three key overhangs and simplifies the Meira story, with the company now having breathing room to push forward late-stage wholly-owned programs in xerostomia and Parkinson’s, as well as the riboswitch program, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MGTX:
- MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million
- MeiraGTx to Participate in Upcoming Investor Conferences
- MeiraGTx Announces Third Quarter 2023 Financial and Operational Results
- MeiraGTx reports Q3 EPS (74c), consensus (55c)
- Biotech Alert: Searches spiking for these stocks today
